Most of the drugs avail able have been used to treat Tourette Syn drome (TS), with lim ited or non ex ist ent re sults un til the ad vent of the neu ro lep tics, which have dem on strated a dis tinctly higher range of ef fec tive ness. Even so, the medi cal treat ment of TS has con sisted of the ad mini stra tion of do pa mine an tagonists, pre domi nantly ha loperi dol, and cen trally act ing alpha-2 ad ren er gic recep tor ago nists, pre domi nantly clonidine. The use of these drugs, how ever, has been lim ited by their ad verse effects-mostly ex tra py ra mi dal, dys phoric symp toms in the case of ha loperi dol (1) and car dio vas cu lar ef fects in the case of clo nidine (2).
Atypi cal an tipsy chot ics have been used to treat TS pa tients. The role of clo zapine in the treat ment of move ment dis orders has been in ves ti gated with ap par ent lack of thera peu tic bene fits for TS patients (3) . Risperi done has been used, with pre domi nantly fa vour able ef fects (4) . Ol an zap ine was con cluded to be a safe and ef fec tive treat ment al ter na tive for TS pa tients (5) . Sert in dol, zi pra sidone, and zo tepine are newer an tipsychot ics not yet avail able in clini cal prac tice. Zi pra si done, how ever, has been in ves ti gated in chil dren and ado lescents with TS, with en cour ag ing re sults and a dem on strated lower risk of ex trapy ra mi dal side ef fects (6) .
Queti apine has not been in ves ti gated for mally in terms of its ef fi cacy for the treat ment of TS. A search of the da ta base of pub lished medi cal lit era ture did not re veal any stud ies evalu at ing the use of queti apine in pa tients with TS.
The clini cal prop er ties of the atypi cal an tipsy chot ics can be ex plained by the phar ma col ogi cal fea ture of com bined 5-HT 2 -D 2 an tago nism. Risperi done, olan zap ine, zi pra si done, and sert in dole dem on strate a higher pro file of D 2 oc cu pancy that is more in keep ing with con ven tional agents such as ha loperi dol, while clo zap ine has rela tively low D 2 activ ity (7) . It has been hy pothe sized that clo zapi ne's lack of ef fi cacy in pa tients with TS could be due to this fac tor. Since queti apine is an atypi cal clozapine-like an tipsy chotic drug with a low do pa mine D 2 receptor-occupancy ra tio and a low af fin ity both for se ro tonin 5-HT 2A re ceptors and for alpha-1 and alpha-2 ad ren ergic re cep tors, the ques tion was to de ter mine its role (if any) in the treatment of pa tients with TS.
We used queti apine to treat 2 chil dren with TS natu ral is ti cally. Each of these chil dren met the DSM-IV di ag nos tic crite ria for TS. Both had been treated with neu ro lep tic drugs for pro longued pe riods of time, with sig nifi cant weight gain, but nei ther had been treated with de pot prepa ra tions. Aside from mo tor and vocal tics, the neu ro logi cal ex ami na tions, in clud ing EEGs, were nor mal for both pa tients. Both chil dren re ceived quetiapine, ad min is tered orally twice daily. The start ing dose was 25 mg twice daily. This was in creased gradu ally to 150 mg daily at day 21 in the first pa tient, and to 100 mg daily at day 21 in the sec ond patient. The pa tients were tested us ing the Yale Global Tic-Severity Scale (YGTSS) for meas ur ing tic fre quency and in ten sity and the Ex tra py ra mi dal Symp tom Rat ing Scale (ESRS) for meas ur ing dyski netic symp toms.
For both pa tients, within 3 weeks vo cal and mo tor tics sig nifi cantly di min ished in fre quency and se ver ity. (On re fer ral, the first pa ti ent's YGTSS score was 79; af ter 3 weeks, it was 38. On re fer ral, the sec ond pa ti ent's YGTSS score was 75; af ter 3 weeks, it was 36.) There were no ex tra py ra mi dal side ef fects meas ured by the ESRS. Both pa tients ini tially reported drowsi ness and de creased ap petite, but these side ef fects gradu ally dis ap peared through out the study. The over all weight loss in both pa tients was at trib uted to the re turn of ap pe tite to a "nor mal" level, rather than to the ef fect of queti apine it self.
The im prove ment of the tics with quetiapine does not ac cord with the ra tio of do pa mine D 2 and se ro tonin 5-HT 2 re ceptor oc cu pancy. This could be due to the fact that, while in vivo D 2 oc cu pancy is the most pre cise means to es tab lish guide lines, not all com pounds (that is, clo zap ine and queti apine) ap pear to require D 2 an tago nism in the same fash ion to at tain the de sired re sponse (7) . Therefore, other ex pla na tions should be ex plored.
One plau si ble ex pla na tion is re lated to the fact that re search ers have cloned at least 5 sub types of the hu man do pa mine re cep tor and 13 sub types of the se rotonin re cep tor. Stud ies of the molecularly cloned do pa mine D 4 re cep tor and se ro tonin 5-HT 6 re cep tor sug gest that clo zapi ne's high af fin ity in bind ing to these sites ex plains the phar ma cologic unique ness of this neu ro lep tic drug (7) and, pos si bly, that of such other clozapine-like neu ro lep tics as quetiapine. An other pos si ble ex pla na tion is that queti apine may work by se lec tive in ac ti va tion of the meso lim bic cor ti cal neu rons, which may also ac count for the low number of ex tra py ra mi dal side effects as so ci ated with its use (8) .
In our sec ond pa tient, the pre treat ment with ha loperi dol posed a con found ing vari able. Some stud ies have con cluded that pre vi ous treat ment with clas si cal an tipsy chot ics (oral and de pot ha loperidol) in flu enced the higher-thanexpected de gree of do pa mine D 2 re ceptor oc cu pancy af ter queti apine treat ment reg is tered even weeks af ter ces sa tion of typi cal neu ro lep tics, sug gest ing that future trial de signs could use fully in clude longer wash out pe ri ods (9) . In the reported case, we started queti apine about 3 weeks af ter ha loperi dol had been dis con tin ued.
Al though the re sults of us ing queti apine to treat these 2 chil dren suf fer ing from TS are en cour ag ing, they should be inter preted with cau tion, given the limi tations posed by the lack of pla cebo tri als, data on drug with drawal, or con trast groups. Spon ta ne ous wax ing and waning of TS symp toms should also be consid ered. Fur ther con trolled stud ies are Humberto C Párraga, MD Marianela I Párraga, MED Springfield, Illinois
Antidepressant-Induced Sexual Dysfunction in Adolescence

Dear Edi tor:
Sex ual dys func tion is a welldocumented side ef fect of most an ti depres sants used to treat adults. The ex act in ci dence of antidepressant-induced sex ual dys func tion is un known, with reports vary ing from as low as 1.9% with fluoxet ine treat ment to as high as 92% with clo mi pramine treat ment. This dispar ity likely re flects the lack of sys tematic study of the sex ual side ef fects of an ti de pres sants. Many prob lems ex ist in as sess ing sex ual dys func tion, in clud ing dif fer ences be tween pa tient self-report and ques tion naire re port, such pos si ble con found ing vari ables as illness-related fac tors, other medi ca tion ef fects, psycho so cial fac tors, and pri mary sex ual dys func tion dis or ders (1) . Sex ual func tion is an im por tant part of ado les cent life. Sur veys of sex ual behav iours, in clud ing in ter course, mu tual or part ner mas tur ba tion, selfmasturbation, and oral sex in di cate that most ado les cents are sexu ally ac tive (2) (3) (4) . The im pact of an ti de pres sants on ado les cent sex ual func tion is, how ever, un known be cause all cur rent stud ies report on adults aged 18 years or older. Yet, the af fec tive and anxi ety dis or ders for which most an ti de pres sants are prescribed of ten have their on set in ado lescence. Fur ther, sex ual dys func tion side ef fects fre quently have an un rec og nized nega tive im pact on treat ment ad her ence. Per sis tent medication-induced sex ual dys func tion may also ad versely af fect ado les cent psy chosex ual de vel op ment.
I re port the cases of 5 pa tients, aged 15 to 18 years, at tend ing out pa tient clin ics at Queen's Uni ver sity, King ston, On tario, and the Medi cal Col lege of Vir ginia Hos pi tals at Vir ginia Com mon wealth Uni ver sity, who were pre scribed an ti depres sant medi ca tion. Af ter giv ing informed con sent, these pa tients were ad min is tered a sem is truc tured in ter view us ing the Changes in Sex ual Func tioning Questionnaire-Interview (CSFQ-I) at weeks 0, 2, 6, 12, and 20 (5, Note 1). Self-reported ad verse events were also re corded.
De scrip tive data for these cases show the fol low ing out comes: 1 case of im provement in sex ual func tion ing in a fe male pa tient tak ing fluvox am ine 50 mg daily, likely sec on dary to im prove ment in dysthymia; 1 case of re ported im provement in sex ual sat is fac tion in a male patient, sec on dary to self-reported in crease in ejacu la tory la tency at trib ut able to paroxet ine 20 mg daily; 1 case of im paired arousal or ex cite ment in a male pa tient tak ing fluvox am ine 50 mg daily, with po ten tial self-reported im pact on treatment ad her ence; 1 case of dose-related de layed ejacu la tion in a male pa tient taking fluvox am ine 150 mg daily, which con trib uted to medi ca tion dis con tinuation; 1 case of no change in sex ual function ing in a male pa tient tak ing ser tra line 25 mg daily. The CSFQ-I scores reflected the change in 3 of the 4 pa tients re port ing a change in sex ual func tion ing.
Changes in sex ual func tion ing do oc cur in ado les cents who are pre scribed an tide pres sant medi ca tions. Of the 5 cases, 4 had some change in sex ual func tion ing over the course of treat ment follow-up. Dif fer ences in the sex ual be hav iours of ado les cents, other con found ing variables in as sess ing sex ual func tion ing (for ex am ple, illness-related ef fects, medi ca tion ef fects, and other psy cho social and in ter per sonal ef fects), and differ ences in self-report com pared with di rect ques tion ing make sys tem atic study of this phe nome non dif fi cult. Because of the varia tion in ado les cent sexual be hav iours over time and the po ten tial im pact of sex ual dys func tion on treat ment ad her ence, I rec om mend re peated di rect ques tion ing of this popula tion re gard ing sex ual func tion ing at base line and through out treat ment. Improved sys tem atic study may re quire the de vel op ment of a ques tion naire designed to as sess sex ual func tion ing in ado les cents. More sys tem atic, controlled study of this popu la tion is re quired.
